{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:13:31Z","timestamp":1793722411659,"version":"4.6.1"},"reference-count":151,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research institute for Convergence of biomedical science and technology, Pusan National University Yangsan Hospital","award":["20-2021-002"],"award-info":[{"award-number":["20-2021-002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peritoneal metastasis, also known as peritoneal carcinomatosis (PC), is a refractory cancer that is typically resistant to conventional therapies. The typical treatment for PC is a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Recently, research in this area has seen significant advances, particularly in immunotherapy as an alternative therapy for PC, which is very encouraging. Catumaxomab is a trifunctional antibody intraperitoneal (IP) immunotherapy authorized in Europe that can be used to diminish malignant ascites by targeting EpCAM. Intraperitoneal (IP) immunotherapy breaks immunological tolerance to treat peritoneal illness. Increasing T-cell responses and vaccination against tumor-associated antigens are two methods of treatment. CAR-T cells, vaccine-based therapeutics, dendritic cells (DCs) in combination with pro-inflammatory cytokines and NKs, adoptive cell transfer, and immune checkpoint inhibitors are promising treatments for PC. Carcinoembryonic antigen-expressing tumors are suppressed by IP administration of CAR-T cells. This reaction was strengthened by anti-PD-L1 or anti-Gr1. When paired with CD137 co-stimulatory signaling, CAR-T cells for folate receptor cancers made it easier for T-cell tumors to find their way to and stay alive in the body.<\/jats:p>","DOI":"10.3390\/cancers15082383","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T05:35:46Z","timestamp":1681968946000},"page":"2383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes"],"prefix":"10.3390","volume":"15","author":[{"given":"Mefotse Saha Cyrelle","family":"Ornella","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea"},{"name":"Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayanasamy","family":"Badrinath","sequence":"additional","affiliation":[{"name":"Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Ae","family":"Kim","sequence":"additional","affiliation":[{"name":"Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euna","family":"Cho","sequence":"additional","affiliation":[{"name":"Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Ho","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea"},{"name":"Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-2537","authenticated-orcid":false,"given":"Jae-Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"ref_1","unstructured":"Willaims, S.C.P. (2022, July 09). Peritoneal Carcinomatosis: Cause, Symptoms, Diagnosis, and Treatment. Available online: https:\/\/www.webmd.com\/cancer\/what-is-peritoneal-carcinomatosis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","article-title":"Peritoneal Carcinomatosis","volume":"19","author":"Coccolini","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43481","DOI":"10.18632\/oncotarget.16480","article-title":"Peritoneal Carcinomatosis: Limits of Diagnosis and the Case for Liquid Biopsy","volume":"8","author":"McMullen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jso.23707","article-title":"Surgical Management of Bowel Obstruction in Patients with Peritoneal Carcinomatosis","volume":"110","author":"Jayakrishnan","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0002-9610(73)90049-4","article-title":"Small Intestinal Obstruction from Peritoneal Carcinomatosis","volume":"125","author":"Glass","year":"1973","journal-title":"Am. J. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","article-title":"Peritoneal Carcinomatosis in Nongynecologic Malignancy. A Prospective Study of Prognostic Factors","volume":"63","author":"Chu","year":"1989","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/bjc.2013.82","article-title":"Impact of Peritoneal Carcinomatosis in the Disease History of Colorectal Cancer Management: A Longitudinal Experience of 2406 Patients over Two Decades","volume":"108","author":"Kerscher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1055-3207(03)00035-8","article-title":"Effective Therapy for Peritoneal Dissemination in Gastric Cancer","volume":"12","author":"Yonemura","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/0284186X.2013.850740","article-title":"Chemotherapy as Palliative Treatment for Peritoneal Carcinomatosis of Gastric Origin","volume":"53","author":"Thomassen","year":"2014","journal-title":"Acta. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","article-title":"Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.bjc.6601586","article-title":"Improved Survival in Patients with Peritoneal Metastases from Colorectal Cancer: A Preliminary Study","volume":"90","author":"Mahteme","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy versus Systemic Chemotherapy and Palliative Surgery in Patients with Peritoneal Carcinomatosis of Colorectal Cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejso.2015.05.018","article-title":"Incidence and Treatment of Recurrent Disease after Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneally Metastasized Colorectal Cancer: A Systematic Review","volume":"41","author":"Nienhuijs","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.soc.2018.02.004","article-title":"Genomics of Peritoneal Malignancies","volume":"27","author":"Karunasena","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cancergen.2017.08.001","article-title":"Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research Network","volume":"216\u2013217","author":"Slavin","year":"2017","journal-title":"Cancer Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/tgh.2020.02.08","article-title":"Molecular Biology and Immunology of Gastric Cancer Peritoneal Metastasis","volume":"5","author":"Yao","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/14737140.2016.1224666","article-title":"The Current Status of Immunotherapy in Peritoneal Carcinomatosis","volume":"16","author":"Heiss","year":"2016","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.3748\/wjg.v22.i30.6829","article-title":"Molecular Mechanisms of Peritoneal Dissemination in Gastric Cancer","volume":"22","author":"Kanda","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0147-0272(79)80008-2","article-title":"Cancer Metastasis: A Product of Tumor-Host Interactions","volume":"3","author":"Sugarbaker","year":"1979","journal-title":"Curr. Probl. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00018-017-2663-1","article-title":"The Peritoneal \u201cSoil\u201d for a Cancerous \u201cSeed\u201d: A Comprehensive Review of the Pathogenesis of Intraperitoneal Cancer Metastases","volume":"75","author":"Uruski","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13193-019-00890-0","article-title":"Peritoneal Carcinomatosis Diagnosis and Treatment in China: Focusing on Training and Collaboration","volume":"10","author":"Li","year":"2019","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal Carcinomatosis from Non-Gynecologic Malignancies: Results of the EVOCAPE 1 Multicentric Prospective Study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","article-title":"A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin","volume":"16","author":"Cao","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-3083.1996.d01-297.x","article-title":"Normal Human Immune Peritoneal Cells: Subpopulations and Functional Characteristics","volume":"44","author":"Kubicka","year":"1996","journal-title":"Scand. J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lfs.2019.01.016","article-title":"Induction of T Cell-Mediated Immune Response by Dendritic Cells Pulsed with MRNA of Sphere-Forming Cells Isolated from Patients with Gastric Cancer","volume":"219","author":"Bagheri","year":"2019","journal-title":"Life Sci."},{"key":"ref_28","first-page":"156","article-title":"Tumor-Associated Macrophages (TAMs) as Biomarkers for Gastric Cancer: A Review","volume":"4","author":"Puolakkainen","year":"2018","journal-title":"Chronic. Dis. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-0393-03","article-title":"ICAM-2 Gene Therapy for Peritoneal Dissemination of Scirrhous Gastric Carcinoma","volume":"10","author":"Tanaka","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fujimori, D., Kinoshita, J., Yamaguchi, T., Nakamura, Y., Gunjigake, K., Ohama, T., Sato, K., Yamamoto, M., Tsukamoto, T., and Nomura, S. (2020). Established Fibrous Peritoneal Metastasis in an Immunocompetent Mouse Model Similar to Clinical Immune Microenvironment of Gastric Cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07477-x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10120-017-0760-3","article-title":"Tumor-Associated Macrophage Infiltration Is Highly Associated with PD-L1 Expression in Gastric Adenocarcinoma","volume":"21","author":"Harada","year":"2018","journal-title":"Gastric Cancer"},{"key":"ref_32","first-page":"5384","article-title":"Accumulation and Suppressive Function of Regulatory T Cells in Malignant Ascites: Reducing their Suppressive Function using Arsenic Trioxide in Vitro","volume":"15","author":"Hu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s40425-019-0708-8","article-title":"Comprehensive Immune Profiling and Immune-Monitoring using Body Fluid of Patients with Metastatic Gastric Cancer","volume":"7","author":"Park","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.18632\/oncotarget.6977","article-title":"Genetic Alterations and their Clinical Implications in Gastric Cancer Peritoneal Carcinomatosis Revealed by Whole-Exome Sequencing of Malignant Ascites","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.11618","article-title":"CD4+CD25+ Regulatory T Cells in Patients with Gastrointestinal Malignancies: Possible Involvement of Regulatory T Cells in Disease Progression","volume":"98","author":"Sasada","year":"2003","journal-title":"Cancer"},{"key":"ref_36","first-page":"881","article-title":"The Contribution of Vascular Endothelial Growth Factor to the Induction of Regulatory T-Cells in Malignant Effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Antcancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J. Med. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/1078-0432.CCR-15-1655","article-title":"Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18","volume":"22","author":"Ma","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e004749","DOI":"10.1136\/jitc-2022-004749","article-title":"Resistance to Systemic Immune Checkpoint Inhibition in the Peritoneal Niche","volume":"10","author":"Chia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","first-page":"PO.17.00073","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA Approval Summary: Pembrolizumab for the First-Line Treatment of Patients with MSI-H\/DMMR Advanced Unresectable or Metastatic Colorectal Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"iv35","DOI":"10.1093\/annonc\/mdz155.130","article-title":"Cancer Immunotherapy with STING Agonist and PD-1 Immune Checkpoint Inhibitor Effectively Suppresses Peritoneal Carcinomatosis of Colon Cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.21873\/invivo.12811","article-title":"Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer","volume":"36","author":"Kumagai","year":"2022","journal-title":"Vivo"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e000857","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic Vaccinia Virus Reinvigorates Peritoneal Immunity and Cooperates with Immune Checkpoint Inhibitor to Suppress Peritoneal Carcinomatosis in Colon Cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wei, H., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, M., Hellstrom, I., and Hellstrom, K.E. (2013). Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084927"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Guo, Z., Wang, X., Cheng, D., Xia, Z., Luan, M., and Zhang, S. (2014). PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089350"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 Blockade and GITR Triggering Induce a Potent Antitumor Immunity in Murine Cancer Models and Synergizes with Chemotherapeutic Drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s10120-015-0579-8","article-title":"Tumor-Associated Macrophages of the M2 Phenotype Contribute to Progression in Gastric Cancer with Peritoneal Dissemination","volume":"19","author":"Yamaguchi","year":"2016","journal-title":"Gastric Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10120-021-01275-5","article-title":"Crosstalk between Cancer-Associated Fibroblasts and Immune Cells in Peritoneal Metastasis: Inhibition in the Migration of M2 Macrophages and Mast Cells by Tranilast","volume":"25","author":"Nakamura","year":"2022","journal-title":"Gastric Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e004001","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and Resistance to Immune Checkpoint Inhibition in DMMR\/MSI-H Metastatic Colorectal and Gastric Cancers","volume":"10","author":"Cohen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bui, Q.L., Mas, L., Hollebecque, A., Tougeron, D., de la Fouchardi\u00e8re, C., Pudlarz, T., Alouani, E., Guimbaud, R., Taieb, J., and Andr\u00e9, T. (2022). Treatments after Immune Checkpoint Inhibitors in Patients with DMMR\/MSI Metastatic Colorectal Cancer. Cancers, 14.","DOI":"10.3390\/cancers14020406"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Barraud, S., Tougeron, D., Villeneuve, L., Eveno, C., Bayle, A., Parc, Y., Pocard, M., Andr\u00e9, T., and Cohen, R. Immune Checkpoint Inhibitors for Patients with Isolated Peritoneal Carcinomatosis from DMMR\/MSI-H Colorectal Cancer, a BIG-RENAPE Collaboration. Dig. Liver Dis. 2022, ahead of print.","DOI":"10.1016\/j.dld.2022.09.015"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"TPS6099","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6099","article-title":"A Phase Ib\/II, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors (CPI) Nivolumab or Pembrolizumab in Adult Patients (Pts) with Advanced Solid Tumors, Including Platinum-Resistant Ovarian Cancer (PROC)","volume":"38","author":"Origuchi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","first-page":"610572","article-title":"Systemic Chemotherapy Including Ramucirumab in Combination with Pressurized Intra-Peritoneal Aerosol Chemotherapy is a Safe Treatment Option for Peritoneal Metastasis of Gastric Cancer","volume":"10","author":"Gronau","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clcc.2015.12.006","article-title":"Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study","volume":"15","author":"Razenberg","year":"2016","journal-title":"Clin. Color. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/IGC.0b013e3181a8331f","article-title":"Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent\/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy","volume":"19","author":"Bellone","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"K\u00f6bel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N.J., Ionescu, D.N., and Rajput, A. (2008). Ovarian Carcinoma Subtypes are Different Diseases: Implications for Biomarker Studies. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050232"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/sj.bjc.6605312","article-title":"Synergistic Anti-Cancer Effects of Immunotoxin and Cyclosporin in Vitro and in Vivo","volume":"101","author":"Andersson","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ijc.20371","article-title":"Downregulation of the Antiapoptotic MCL-1 Protein and Apoptosis in MA-11 Breast Cancer Cells Induced by an Anti-Epidermal Growth Factor Receptor-Pseudomonas Exotoxin a Immunotoxin","volume":"112","author":"Andersson","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/bjc.2015.380","article-title":"Phase I Trial of EpCAM-Targeting Immunotoxin MOC31PE, Alone and in Combination with Cyclosporin","volume":"113","author":"Andersson","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1757-2215-7-23","article-title":"The MOC31PE Immunotoxin Reduces Cell Migration and Induces Gene Expression and Cell Death in Ovarian Cancer Cells","volume":"7","author":"Wiiger","year":"2014","journal-title":"J. Ovarian Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1245\/s10434-017-5814-6","article-title":"Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial","volume":"24","author":"Andersson","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.28158","article-title":"Immunotoxin Targeting EpCAM Effectively Inhibits Peritoneal Tumor Growth in Experimental Models of Mucinous Peritoneal Surface Malignancies","volume":"133","author":"Flatmark","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2019.04.014","article-title":"ImmunoPeCa Trial: Long-Term Outcome Following Intraperitoneal MOC31PE Immunotoxin Treatment in Colorectal Peritoneal Metastasis","volume":"47","author":"Andersson","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"61800","DOI":"10.18632\/oncotarget.18694","article-title":"MOC31PE Immunotoxin\u2014Targeting Peritoneal Metastasis from Epithelial Ovarian Cancer","volume":"8","author":"Andersson","year":"2017","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1245\/s10434-021-10022-0","article-title":"Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"28","author":"Thorgersen","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jso.21338","article-title":"Intraperitoneal Immunotherapy to Prevent Peritoneal Carcinomatosis in Patients with Advanced Gastrointestinal Malignancies","volume":"100","author":"Heiss","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/0008-5472.CAN-11-2235","article-title":"Immunomonitoring Results of a Phase II\/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM \u00d7 Anti-CD3)","volume":"72","author":"Schoberth","year":"2012","journal-title":"Cancer Res."},{"key":"ref_72","first-page":"483","article-title":"Immunotherapy of Peritoneal Carcinomatosis","volume":"134","author":"Heiss","year":"2007","journal-title":"Cancer Treat. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4161\/mabs.2.3.11791","article-title":"Structural and Functional Characterization of the Trifunctional Antibody Catumaxomab","volume":"2","author":"Chelius","year":"2010","journal-title":"MAbs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7150\/jca.2.309","article-title":"Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab\u00ae)","volume":"2","author":"Seimetz","year":"2011","journal-title":"J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The Trifunctional Antibody Catumaxomab for the Treatment of Malignant Ascites Due to Epithelial Cancer: Results of a Prospective Randomized Phase II\/III Trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ijc.21165","article-title":"Immunotherapy of Malignant Ascites with Trifunctional Antibodies","volume":"117","author":"Heiss","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Thadi, A., Khalili, M., Morano, W.F., Richard, S.D., Katz, S.C., and Bowne, W.B. (2018). Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. Vaccines, 6, Erratum in Vaccines 2019, 7, 15.","DOI":"10.3390\/vaccines7010015"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Bezan, A., Hohla, F., Meissnitzer, T., and Greil, R. (2013). Systemic Effect of Catumaxomab in a Patient with Metastasized Colorectal Cancer: A Case Report. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-618"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-9966-28-18","article-title":"Induction of Anti-Tumor Immunity by Trifunctional Antibodies in Patients with Peritoneal Carcinomatosis","volume":"28","author":"Siegel","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_80","first-page":"833","article-title":"A Phase II Study of Catumaxomab Administered Intra- and Postoperatively as Part of a Multimodal Approach in Primarily Resectable Gastric Cancer","volume":"18","author":"Bokemeyer","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical Pharmacology and Translational Aspects of Bispecific Antibodies","volume":"10","author":"Trivedi","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM \u00d7 Anti-CD3 Antibody: A Phase I\/II Study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_83","first-page":"474","article-title":"Malignant Ascites: Demographics, Therapeutic Efficacy and Predictors of Survival","volume":"6","author":"Mackey","year":"1996","journal-title":"Can. J. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in Quality of Life (QoL) in Patients with Malignant Ascites: Results from a Phase II\/III Study Comparing Paracentesis plus Catumaxomab with Paracentesis Alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised Phase II Trial to Investigate Catumaxomab (Anti-EpCAM\u2009\u00d7\u2009Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients with Gastric Cancer","volume":"119","author":"Kunzmann","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the Corner on Therapeutic Cancer Vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","article-title":"Cellular Vaccine Approaches","volume":"16","author":"Le","year":"2010","journal-title":"Cancer J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing Oncolytic Virotherapy in Cancer Treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","article-title":"From Immune Checkpoints to Vaccines: The Past, Present and Future of Cancer Immunotherapy","volume":"143","author":"Osipov","year":"2019","journal-title":"Adv. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ajps.2019.10.006","article-title":"Nanoparticle Cancer Vaccines: Design Considerations and Recent Advances","volume":"15","author":"Liu","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_93","first-page":"4272","article-title":"The Clinical Effects of Dendritic Cell Vaccines Combined with Cytokine-Induced Killer Cells Intraperitoneal Injected on Patients with Malignant Ascites","volume":"7","author":"Ai","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jcyt.2013.05.022","article-title":"Intraperitoneal Delivery of Human Natural Killer Cells for Treatment of Ovarian Cancer in a Mouse Xenograft Model","volume":"15","author":"Geller","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Denman, C.J., Senyukov, V.V., Somanchi, S.S., Phatarpekar, P.V., Kopp, L.M., Johnson, J.L., Singh, H., Hurton, L., Maiti, S.N., and Huls, M.H. (2012). Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030264"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","article-title":"Natural Killer Cells Stimulated with PM21 Particles Expand and Biodistribute in Vivo: Clinical Implications for Cancer Treatment","volume":"18","author":"Oyer","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant Ascites: A Review of Prognostic Factors, Pathophysiology and Therapeutic Measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clim.2009.08.007","article-title":"Autologous MUC1-Specific Th1 Effector Cell Immunotherapy Induces Differential Levels of Systemic TReg Cell Subpopulations That Result in Increased Ovarian Cancer Patient Survival","volume":"133","author":"Dobrzanski","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10555-013-9423-y","article-title":"The Role of Tumour-Associated MUC1 in Epithelial Ovarian Cancer Metastasis and Progression","volume":"32","author":"Deng","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/2326-6066.CIR-16-0162","article-title":"NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine","volume":"5","author":"Alkayyal","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"52207","DOI":"10.18632\/oncotarget.10537","article-title":"A Folate Receptor-Targeted Lipoplex Delivering Interleukin-15 Gene for Colon Cancer Immunotherapy","volume":"7","author":"Liang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-10-0590","article-title":"Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity","volume":"9","author":"Gujar","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2012.228","article-title":"Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis through Virus-Induced Immunomodulation","volume":"21","author":"Gujar","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_104","first-page":"69","article-title":"Reovirus in Cancer Therapy: An Evidence-Based Review","volume":"3","author":"Clements","year":"2014","journal-title":"Oncol. Virother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/1078-0432.CCR-13-3361","article-title":"P53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates P53-Specific CD8+ T-Cell Responses","volume":"20","author":"Hardwick","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e958949","DOI":"10.4161\/21624011.2014.958949","article-title":"Overcoming Immunosuppression to Enhance a P53MVA Vaccine","volume":"3","author":"Hardwick","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CJI.0b013e31816dad10","article-title":"A Multipeptide Vaccine Is Safe and Elicits T-Cell Responses in Participants with Advanced Stage Ovarian Cancer","volume":"31","author":"Irvin","year":"2008","journal-title":"J. Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-Engineered T Cells for Cancer Therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical Development of CAR T Cells-Challenges and Opportunities in Translating Innovative Treatment Concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-Specific CAR T Cells in Gastrointestinal Cancers: Phase 1 Trial Interim Results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/10428194.2020.1786563","article-title":"Patient Selection for Chimeric Antigen Receptor (CAR) T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas","volume":"61","author":"Johnson","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus. Med. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40273-019-00799-0","article-title":"Tisagenlecleucel for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","volume":"37","author":"Walton","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T Cell Infusions for Peritoneal Carcinomatosis Are Superior to Systemic Delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.18632\/oncotarget.14592","article-title":"Intraperitoneal Immunotherapy with T Cells Stably and Transiently Expressing Anti-EpCAM CAR in Xenograft Models of Peritoneal Carcinomatosis","volume":"8","author":"Ang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41598-020-79721-0","article-title":"Intraperitoneal Collagenase as a Novel Therapeutic Approach in an Experimental Model of Colorectal Peritoneal Carcinomatosis","volume":"11","author":"Barambio","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.-R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin Is a Target of Chimeric Antigen Receptor T Cells for Treating Gastric Cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_127","first-page":"106","article-title":"Antitumor Effects and Persistence of a Novel HER2 CAR T Cells Directed to Gastric Cancer in Preclinical Models","volume":"8","author":"Han","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.omto.2020.08.009","article-title":"Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer","volume":"18","author":"Jung","year":"2020","journal-title":"Mol. Ther. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-Cell Therapy for CEA+ Liver Metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fimmu.2012.00208","article-title":"Myeloid-Derived Suppressor Cells: Mechanisms of Action and Recent Advances in Their Role in Transplant Tolerance","volume":"3","author":"Dilek","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia","volume":"21","author":"Lee","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the Folate Receptor: Diagnostic and Therapeutic Approaches to Personalize Cancer Treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_138","first-page":"6457","article-title":"Expression of Multiple Immune Checkpoint Molecules on T Cells in Malignant Ascites from Epithelial Ovarian Carcinoma","volume":"15","author":"Imai","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 Secreting Tumor-Targeted Chimeric Antigen Receptor T Cells Eradicate Ovarian Tumors in Vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Hong, H., Brown, C.E., Ostberg, J.R., Priceman, S.J., Chang, W.-C., Weng, L., Lin, P., Wakabayashi, M.T., Jensen, M.C., and Forman, S.J. (2016). L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146885"},{"key":"ref_142","first-page":"26","article-title":"L1 (CAM) (CD171) in Ovarian Serous Neoplasms","volume":"29","author":"Daponte","year":"2008","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_143","first-page":"7624","article-title":"Nanobody-Based CAR T Cells That Target the Tumor Microenvironment Inhibit the Growth of Solid Tumors in Immunocompetent Mice","volume":"116","author":"Xie","year":"2019","journal-title":"Biol. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1806009","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential Lung Attack and Lethality Generated by EpCAM-Specific CAR-T Cells in Immunocompetent Mouse Models","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T Cell-Mediated Depletion of Immunosuppressive Tumor-Associated Macrophages Promotes Endogenous Antitumor Immunity and Augments Adoptive Immunotherapy","volume":"12","author":"Lynn","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e003737","DOI":"10.1136\/jitc-2021-003737","article-title":"Delivery of CD47 Blocker SIRP\u03b1-Fc by CAR-T Cells Enhances Antitumor Efficacy","volume":"10","author":"Chen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Shariati, M., Willaert, W., Ceelen, W., De Smedt, S.C., and Remaut, K. (2019). Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis. Cancers, 11.","DOI":"10.3390\/cancers11070906"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12951-022-01300-4","article-title":"Carrier-Free Multifunctional Nanomedicine for Intraperitoneal Disseminated Ovarian Cancer Therapy","volume":"20","author":"Huang","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1039\/D1NR06518A","article-title":"Nanotherapeutic Macrophage-Based Immunotherapy for the Peritoneal Carcinomatosis of Lung Cancer","volume":"14","author":"Wang","year":"2022","journal-title":"Nanoscale"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1021\/acsami.2c19769","article-title":"Engineered Apoptosis-Bioinspired Nanoparticles Initiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites","volume":"15","author":"Huang","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:19:39Z","timestamp":1760123979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":151,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15082383"],"URL":"https:\/\/doi.org\/10.3390\/cancers15082383","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}